CircRERE Confers the Resistance of Multiple Myeloma to Bortezomib Depending on the Regulation of CD47 by Exerting the Sponge Effect on MiR-152-3p

Overview

Journal J Bone Oncol

Publisher Elsevier

Date 2021 Jul 26

PMID 34307012

Citations 10

Authors

Wei Fang

Jiao Mu

Yi Yang

Lin Liu

Affiliations

Soon will be listed here.

Abstract

Background: Inevitable resistance to chemotherapeutic drugs has become a major obstacle for the clinical treatment of multiple myeloma (MM). Circular RNAs (circRNAs) can regulate the chemoresistance in different tumors. Our study was to explore the regulation of circRNA arginine-glutamic acid dipeptide repeats (circRERE) in bortezomib (BTZ) resistance of MM.

Methods: CircRERE, microRNA-152-3p (miR-152-3p) and cluster of differentiation 47 (CD47) levels were assayed through the quantitative real-time polymerase chain reaction (qRT-PCR). Cell sensitivity to BTZ was analyzed using Cell Counting Kit-8 (CCK-8) assay. Cell proliferation and apoptosis were determined via colony formation assay and flow cytometry, respectively. The detection of all proteins was conducted by western blot. The target binding was analyzed via the dual-luciferase reporter assay and RIP assay.

Results: We found the upregulation of circRERE in BTZ-resistant MM samples and cells. BTZ resistance was inhibited after circRERE expression was downregulated in MM cells. CircRERE was identified to act as a miR-152-3p sponge. The effect of circRERE on the BTZ resistance was associated with the sponge function for miR-152-3p. CD47 was a target for miR-152-3p and circRERE could sponge miR-152-3p to generate the expression regulation of CD47. MiR-152-3p facilitated the susceptibility of MM cells to BTZ by targeting CD47.

Conclusion: These results suggested that circRERE could suppress the BTZ resistance in MM cells by mediating the miR-152-3p/CD47 axis.

Citing Articles

Circular RNA as Diagnostic and Prognostic Biomarkers in Hematological Malignancies:Systematic Review.

Gao L, Fan J, He J, Fan W, Che X, Wang X Technol Cancer Res Treat. 2024; 23:15330338241285149.

PMID: 39512224 PMC: 11544746. DOI: 10.1177/15330338241285149.

Recent Progress of CircRNAs in Hematological Malignancies.

Cui Y, Wang L, Xu J, Nan H, Yang P, Niu J Int J Med Sci. 2024; 21(13):2544-2561.

PMID: 39439468 PMC: 11492881. DOI: 10.7150/ijms.98156.

Circular RNAs in tumor immunity and immunotherapy.

Zhang W, Xu C, Yang Z, Zhou J, Peng W, Zhang X Mol Cancer. 2024; 23(1):171.

PMID: 39169354 PMC: 11337656. DOI: 10.1186/s12943-024-02082-z.

Systematic loss-of-function screens identify pathway-specific functional circular RNAs.

Liu L, Neve M, Perlaza-Jimenez L, Xi X, Purcell J, Hawdon A Nat Cell Biol. 2024; 26(8):1359-1372.

PMID: 39095657 DOI: 10.1038/s41556-024-01467-y.

Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks.

Meng L, Wu H, Wu J, Ding P, He J, Sang M Cell Death Dis. 2024; 15(1):3.

PMID: 38177102 PMC: 10766988. DOI: 10.1038/s41419-023-06389-5.

References

Zheng S, Huang Q, Zheng Z, Zhang Z, Guo G . circGFRA1 affects the sensitivity of triple-negative breast cancer cells to paclitaxel via the miR-361-5p/TLR4 pathway. J Biochem. 2021; 169(5):601-611. DOI: 10.1093/jb/mvaa148. View

Sun Y, Cao Z, Shan J, Gao Y, Liu X, Ma D . Hsa_circ_0020095 Promotes Oncogenesis and Cisplatin Resistance in Colon Cancer by Sponging miR-487a-3p and Modulating SOX9. Front Cell Dev Biol. 2021; 8:604869. PMC: 7844065. DOI: 10.3389/fcell.2020.604869. View

Zhang L, Zhang Y, Wang Y, Zhao Y, Ding H, Li P . Circular RNAs: Functions and Clinical Significance in Cardiovascular Disease. Front Cell Dev Biol. 2020; 8:584051. PMC: 7550538. DOI: 10.3389/fcell.2020.584051. View

Guo M, Li S, Zhao X, Yuan Y, Zhang B, Guan Y . Knockdown of Circular RNA Hsa_circ_0000714 Can Regulate RAB17 by Sponging miR-370-3p to Reduce Paclitaxel Resistance of Ovarian Cancer Through CDK6/RB Pathway. Onco Targets Ther. 2020; 13:13211-13224. PMC: 7769200. DOI: 10.2147/OTT.S285153. View

Liu Y, Liu X, Lin C, Jia X, Zhu H, Song J . Noncoding RNAs regulate alternative splicing in Cancer. J Exp Clin Cancer Res. 2021; 40(1):11. PMC: 7789004. DOI: 10.1186/s13046-020-01798-2. View

Rastgoo N, Wu J, Liu A, Pourabdollah M, Atenafu E, Reece D . Targeting CD47/TNFAIP8 by miR-155 overcomes drug resistance and inhibits tumor growth through induction of phagocytosis and apoptosis in multiple myeloma. Haematologica. 2020; 105(12):2813-2823. PMC: 7716364. DOI: 10.3324/haematol.2019.227579. View

Fan C, Liu X, Li W, Wang H, Teng Y, Ren J . Circular RNA circ KMT2E is up-regulated in diabetic cataract lenses and is associated with miR-204-5p sponge function. Gene. 2019; 710:170-177. DOI: 10.1016/j.gene.2019.05.054. View

Rodrigues-Junior D, Pelarin M, Nader H, Vettore A, Pinhal M . MicroRNA-1252-5p Associated with Extracellular Vesicles Enhances Bortezomib Sensitivity in Multiple Myeloma Cells by Targeting Heparanase. Onco Targets Ther. 2021; 14:455-467. PMC: 7814994. DOI: 10.2147/OTT.S286751. View

Li X, Yang B, Ren H, Xiao T, Zhang L, Li L . Hsa_circ_0002483 inhibited the progression and enhanced the Taxol sensitivity of non-small cell lung cancer by targeting miR-182-5p. Cell Death Dis. 2019; 10(12):953. PMC: 6915566. DOI: 10.1038/s41419-019-2180-2. View

10.

Song Y, Hu N, Song X, Yang J . Hsa_Circ_0007841 Enhances Multiple Myeloma Chemotherapy Resistance Through Upregulating ABCG2. Technol Cancer Res Treat. 2020; 19:1533033820928371. PMC: 7307286. DOI: 10.1177/1533033820928371. View

11.

Storti P, Vescovini R, Costa F, Marchica V, Toscani D, Palma B . CD14 CD16 monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy. Br J Haematol. 2020; 190(3):430-436. DOI: 10.1111/bjh.16548. View

12.

Zhang Y, Wang H, Li C, Gao L, Zheng Y, Chang W . CircSMYD4 regulates proliferation, migration and apoptosis of hepatocellular carcinoma cells by sponging miR-584-5p. Cancer Cell Int. 2020; 20(1):556. PMC: 7678128. DOI: 10.1186/s12935-020-01648-3. View

13.

Schuster S, Hsieh A . The Untranslated Regions of mRNAs in Cancer. Trends Cancer. 2019; 5(4):245-262. PMC: 6465068. DOI: 10.1016/j.trecan.2019.02.011. View

14.

Ogoyama M, Ohkuchi A, Takahashi H, Zhao D, Matsubara S, Takizawa T . LncRNA -Derived Accelerates the Invasion of Extravillous Trophoblast Cells by Inhibiting and Subsequently Activating Matrix Metalloproteinases. Int J Mol Sci. 2021; 22(3). PMC: 7866107. DOI: 10.3390/ijms22031237. View

15.

Zhang L, Rastgoo N, Wu J, Zhang M, Pourabdollah M, Zacksenhaus E . MARCKS inhibition cooperates with autophagy antagonists to potentiate the effect of standard therapy against drug-resistant multiple myeloma. Cancer Lett. 2020; 480:29-38. DOI: 10.1016/j.canlet.2020.03.020. View

16.

Gonzalez-Santamarta M, Quinet G, Reyes-Garau D, Sola B, Roue G, Rodriguez M . Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma. Adv Exp Med Biol. 2020; 1233:153-174. DOI: 10.1007/978-3-030-38266-7_6. View

17.

Li Y, Zhang Y, Zhang S, Huang D, Li B, Liang G . circRNA circARNT2 Suppressed the Sensitivity of Hepatocellular Carcinoma Cells to Cisplatin by Targeting the miR-155-5p/PDK1 Axis. Mol Ther Nucleic Acids. 2021; 23:244-254. PMC: 7772525. DOI: 10.1016/j.omtn.2020.08.037. View

18.

Buzzeo R, Enkemann S, Nimmanapalli R, Alsina M, Lichtenheld M, Dalton W . Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341. Clin Cancer Res. 2005; 11(16):6057-64. DOI: 10.1158/1078-0432.CCR-04-2685. View

19.

Luo Y, Gui R . Circulating Exosomal CircMYC Is Associated with Recurrence and Bortezomib Resistance in Patients with Multiple Myeloma. Turk J Haematol. 2020; 37(4):248-262. PMC: 7702652. DOI: 10.4274/tjh.galenos.2020.2020.0243. View

20.

Sun J, Muz B, Alhallak K, Markovic M, Gurley S, Wang Z . Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma. Cancers (Basel). 2020; 12(2). PMC: 7072283. DOI: 10.3390/cancers12020305. View